BRCA1 and ovarian carcinoma: To further evaluate whether BRCA1 is important for this combination, we examined the effects of GSK3i (LY or CHIR) or PARPi SP alone or their combination on cell viability in a pair of ovarian cancer UWB1.289 (carrying a BRCA1 mutation, BRCA1-null), and UWB1.289 + BRCA1 cells, in which wild-type BRCA1 was restored.